Correspondence 0001013762-25-001604 from Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc.
Date: March 24, 2025 · CIK: 0001788028 · Accession: 0001013762-25-001604
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285914
Letter
Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102
Redwood City, CA 94065
March 24, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-0406
Attention: Tim Buchmiller
Re: Jasper Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 19, 2025
File No. 333-285914
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Jasper Therapeutics, Inc. (the " Company ") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-285914) of the Company, filed with the Securities and Exchange Commission on March 19, 2025 (the " Registration Statement "), be accelerated so that the Registration Statement shall become effective at 4:30 p.m., Eastern Time, on March 26, 2025 or as soon as possible thereafter.
The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Samantha H. Eldredge of Paul Hastings LLP, by telephone at (650) 320-1838 or by email at samanthaeldredge@paulhastings.com. The Company hereby authorizes Ms. Eldredge to orally modify or withdraw this request for acceleration.
Sincerely,
JASPER THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 March 24, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attention: Tim Buchmiller Re: Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed March 19, 2025 File No. 333-285914 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Jasper Therapeutics, Inc. (the " Company ") hereby respectfully requests that the effectiveness of the Registration Statement on Form S-3 (File No. 333-285914) of the Company, filed with the Securities and Exchange Commission on March 19, 2025 (the " Registration Statement "), be accelerated so that the Registration Statement shall become effective at 4:30 p.m., Eastern Time, on March 26, 2025 or as soon as possible thereafter. The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Samantha H. Eldredge of Paul Hastings LLP, by telephone at (650) 320-1838 or by email at samanthaeldredge@paulhastings.com. The Company hereby authorizes Ms. Eldredge to orally modify or withdraw this request for acceleration. Sincerely, JASPER THERAPEUTICS, INC. By: /s/ Herb Cross Herb Cross Chief Financial Officer cc: Samantha H. Eldredge, Esq. (Paul Hastings LLP)